The Omnipod® 5 System is the first wearable, on-body, tubeless, hybrid closed loop system integrated with Dexcom G6 approved in Europe for use in people with Type 1 diabetes, aged 2 and above. The Omnipod® 5 System works with the Dexcom G6 Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to your personal needs.

Automated Insulin Delivery (AID) refers to a system that is able to automatically adjust insulin delivery based on glucose readings from an integrated glucose monitor.

Within this there are Hybrid Closed Loop (HCL) systems. These automatically adjust basal insulin based on glucose readings from an integrated glucose monitor, with the user manually delivering bolus insulin to cover meals.

Currently, all available AID systems on the market are HCLs, which mean that there is still a need to manually deliver bolus insulin at mealtimes. Therefore, you may hear these 2 terms used interchangeably

We are delighted to announce that Omnipod 5 has now received CE mark in Europe. However, this is the first step of bringing this product to market. The next key step is to work with authorities to secure access and availability through the healthcare systems. Insulet has announced UK and Germany as the first European countries to launch the Omnipod 5 system in mid- respectively end of 2023. 
Other European countries, including the Nordics, can expect product launch during 2024. 
There is no detailed timeline for the Nordic countries yet. 

At this stage, as we work on getting the product available in your country, we are still working on providing the knowledge to your health care team to be fully prepared at that time.

Register your interest here to be kept up to date on the latest information and product availability in your country.

Choice and access to technology for people living with Type 1 diabetes is of the upmost importance for Nordic Infucare, and so we will continue to supply both Omnipod DASH^® and Omnipod 5 systems, recognising the needs and preferences of HCPs and people living with diabetes.